The quest for transparency in the relationships between life sciences companies and healthcare professionals is quickly becoming a global movement. Reporting requirements for financial interactions have been prevalent in the United States for many years, but the movement is spreading throughout the world to places like Japan, Australia, and Europe. In France, the government passed a law that imposes burdensome reporting requirements. Industry groups across Europe, most notably the European Federation of Pharmaceutical Industries and Associations, are acting aggressively to try to forestall more government laws by adopting industry-developed disclosure systems. These activities will affect many different segments of the European healthcare system.